arrow
T

Tsai-Yuan Hsieh

chi mei hospital
H指数:31
被引数:2,981

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C

高正常值范围及异常丙氨酸转氨酶水平与慢性丙型肝炎治疗后肝癌风险增加相关

2026-04-012
OAAI
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
2023-03-278
OAAI
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Sofosbuvir/velpatasvir/voxilaprevir用于先前接受NS5A直接作用抗病毒药物治疗的慢性丙型肝炎病毒感染患者: 台湾真实世界的多中心队列

2023-01-2614
OA
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
2022-05-0123
PRE
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
2022-02-074
OAAI
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
2021-12-0613
OAAI
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
2021-10-0112
OAAI
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
2021-03-1237
OAAI
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

Sofosbuvir/velpatasvir治疗慢性丙型肝炎病毒感染和代偿性肝病患者: 台湾的真实数据

2021-03-0621
OAAI
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

4年恩替卡韦治疗可降低慢性乙型肝炎患者的肝细胞癌,肝硬化事件和死亡率

2016-10-04180
PREAI